Meg Macarthur, Senior Policy Officer at Breakthrough Breast Cancer says: “The threat to breast care and other specialist nurses is potentially devastating to patients. We know that these nurses play a significant role in their care and recovery, offering an invaluable service throughout their treatment journey… Read Full Article

Ark Therapeutics Group plc (AKT: LSE) (“Ark” or “the Company”), announces that it has filed documentation with the European Medicines Agency (“EMA”) in relation to its request for re-examination of the marketing approval application (“MAA”) for Cerepro®, Ark’s novel gene based therapy for the treatment of operable malignant glioma (brain cancer)… Read...

Meg Macarthur, Senior Policy Officer at Breakthrough Breast Cancer says: “The threat to breast care and other specialist nurses is potentially devastating to patients. We know that these nurses play a significant role in their care and recovery, offering an invaluable service throughout their treatment journey… Read Full Article

Genta Incorporated (OTCBB: GETA) announced that the Company has initiated a new dose-ranging study of tesetaxel, the Company’s novel oral tubulin inhibitor, using a weekly dosing regimen. Tesetaxel — a late Phase 2 oncology product — is the leading oral taxane currently in clinical development… Read Full Article

Researchers have found that one particularly aggressive type of blood cancer, mixed lineage leukemia (MLL), has an unusual way to keep the molecular motors running. The cancer cells rely on the normal version of an associated protein to stay alive. MLL happens when a piece of chromosome 11 breaks off at the normal MLL-associated gene… Read Full Article

Adam Berger, M.D., a Cancer Liaison Physician (CLP) at Thomas Jefferson University Hospital, recently received an Outstanding Performance Award for going above and beyond the scope of the normal duties of serving as a liaison between the hospital’s cancer program and the American College of Surgeons Commission on Cancer (CoC)… Read Full Article

The National Institutes of Health has awarded the Virginia Commonwealth Massey Cancer Center a National Cancer Institute grant totaling nearly $3 million to develop a standardized test to measure health literacy among cancer patients. The four-year grant will be led by Levent Dumenci, Ph.D… Read Full Article

Researchers have found that one particularly aggressive type of blood cancer, mixed lineage leukemia (MLL), has an unusual way to keep the molecular motors running. The cancer cells rely on the normal version of an associated protein to stay alive. MLL happens when a piece of chromosome 11 breaks off at the normal MLL-associated gene… Read Full Article

ProUroCare Medical, Inc. (OCT Bulletin Board: PUMD, PUMDU, PUMDW), a provider of proprietary medical imaging products, indicates that the Food and Drug Administration has informed the industry that the processing of 510(k) applications, which includes the ProUroScan™ prostate imaging system, has been delayed because of the inclement weather in February that impacted the Washington, D.C… Read...

UroToday.com – Treatment decisions in prostate cancer are guided by Gleason grade and laterality (unilateral vs. bilateral) findings on prostate needle biopsy which samples a small proportion of the prostate. Surgical decisions with respect to nerve sparing and lymph node dissection are also influenced by prostate biopsy findings… Read Full Article